[명화감상] 한미순 작 〈바람꽃 일기〉

한미순 새가정사 1997 새가정 Vol.- No.-

시각적 자극과 연하체조가 장기요양시설 뇌졸중 노인의 연하기능에 미치는 효과

한미순,김화순,이영휘,김수현 한국노인간호학회 2013 노인간호학회지 Vol.15 No.3

Purpose: This study was done to investigate effects on swallowing function following visual stimulation and swallowing promotion exercises before meals for elders with swallowing difficulties following stroke. Methods: Participants for this nonequivalent control pre-post test design were 72 elders with stroke. Convenience sampling method was used to assign participants to experimental (36) and control (36) groups. The intervention was provided for about 15 minutes at every lunch and dinner time for 4 weeks. Outcome variables were Gugging Swallowing Screen (GUSS) score, body weight, total caloric intake, self-efficacy for swallowing, and coughing episodes during meal times. Results: Fifty-one participants were women (72.9%) and 74.3% were stroke only patients. Patients in the experimental group took less time to finish their meals and a higher percent had solid chopped food compared to the control group. Differences were statistically significant. In ANCOVA analysis using GUSS score as a covariate, the only significant improvement after the intervention was self-efficacy for swallowing. Conclusion: Visual stimulation and swallowing promotion exercises could lead to improvement in self-efficacy for swallowing even if they did not decrease coughing episodes during meal time.

자동화 검사법으로 측정한 혈청 히알루론산의 평가: 류마티스관절염 진단을 위한

한미순,박용정,김현숙 대한진단검사의학회 2014 Laboratory Medicine Online Vol.4 No.2

배경: 히알루론산은 결합조직에 존재하면서 윤활제 기능을 하며, 관절에 염증이 발생하면 윤활액과 혈청 모두에서 농도가 증가하는 것으로 알려져 있다. 본 연구에서는 자동화 분석법으로 혈청 히알루론산 농도를 측정하고 이의 참고구간 설정 및 류마티스관절염의 진단을 위한 표지자로서의 유용성을 평가하였다. 방법: 건강인 121명과 환자 253명의 혈청 검체에서 LPIAACE 시약 (Mitsubishi, Japan)과 LT Auto Wako (Wako, Japan) 시약을 사용한 두 종류의 자동화 정량검사를 이용하여 히알루론산 농도를 측정하였다. 혈청 히알루론산 농도와 류마티스관절염의 진단 간의 관련성을 ROC 곡선과 다변량로지스틱회귀분석을 사용하여 평가하였다. 결과: 혈청 히알루론산 농도의 95 백분위수 상위 참고구간은 LPIAACE 시약에서는 57.28 ng/mL (90% CI, 46.30-68.20), LT Auto Wako 시약은 72.64 ng/mL (90% CI, 57.30-85.70)였다. 류마티스관절염군과 기타 전체 대상군을 감별하기 위한 혈청 히알루론산의 AUC는 LPIAACE 시약의 경우 0.68, LT Auto Wako 시약의 경우 0.70이었다. 류마티스관절염을 예측하는 데 있어 혈청 히알루론산 농도의 OR은 LPIAACE 시약의 경우 1.02 (95% CI, 1.02-1.04), LT Auto Wako 시약은 1.03 (95% CI, 1.02-1.05)이었다. 결론: 본 연구에서는 한국인의 혈청 히알루론산 농도의 성인 참고구간을 제시하였다. 혈청 히알루론산은 류마티스관절염과 건강인 및 기타 관절염의 감별을 위한 보완적인 표지자로서 도움이 될 것으로 사료된다. Background: Hyaluronic acid (HA) is present in the connective tissues wherein it functions as a lubricant. HA is known to be increased in both synovial fluid and serum when inflammation occurs in the joint. We measured serum HA concentrations by automated assays and determined its reference interval and its usefulness as a diagnostic marker in patients with rheumatoid arthritis (RA). Methods: Serum specimens collected from 121 healthy individuals and 253 patients with various arthritis were used for measuring HA with two automated assays, namely, LPIAACE (Mitsubishi, Japan) and LT Auto Wako (Wako, Japan). The association between serum HA concentration and the diagnosis of RA was estimated by receiver operator characteristic (ROC) analysis and multivariate logistic regression. Results: The 95th percentile upper reference limit of serum HA was 57.28 ng/mL (90% confidence interval [CI], 46.30-68.20 ng/mL) for LPIAACE and 72.64 ng/mL (90% CI, 57.30-85.70 ng/mL) for LT Auto Wako. Area under the ROC curve values of serum HA for discriminating the RA group from the non-RA group were 0.68 for LPIAACE and 0.70 for LT Auto Wako. The odds ratio for serum HA in predicting RA was 1.02 (95% CI, 1.02-1.04) for LPIAACE and 1.03 (95% CI, 1.02-1.05) for LT Auto Wako. Conclusions: This study provides a reference interval for serum HA concentrations in Koreans. This result suggests that the serum HA concentrations could be helpful as a complementary marker for discriminating RA from other types of arthritis, as well as distinguishing patients with RA from healthy controls.

Comparison of the QIAGEN artus HBV QS-RGQ Assay With the Roche COBAS AmpliPrep/COBAS TaqMan HBV Assay for Quantifying Viral DNA in Sera of Chronic Hepatitis B Patients

한미순,박용정,나현진,김현숙 대한진단검사의학회 2017 Annals of Laboratory Medicine Vol.37 No.3

Background: Hepatitis B virus DNA quantification is essential for managing chronic hepatitis B (CHB). We compared the performance of artus HBV QS-RGQ (QIAGEN GmbH, Germany) and CAP/CTM v2.0 HBV assays (Roche Molecular Diagnostics, USA) in CHB patients. Methods: A comparative evaluation between two assays was performed with 508 clinical serum samples. Precision, linearity, and the limit of detection (LOD) of QS-RGQ assay was evaluated by using the WHO standard 97/750 and clinical samples. Results: Detection rates and viral loads as determined QS-RGQ assay were significantly lower than those from the CAP/CTM v2.0 assay (52.8% vs 60.6%; 3.55±1.77 IU/mL vs 4.18±1.89 IU/mL, P<0.0001). The kappa coefficient between qualitative results was 0.79 (95% confidence interval, 0.74 to 0.85). Bland-Altman plot found a mean difference of (QS-RGQ - CAP/CTM v2.0)=–0.63 log10 IU/mL (95% limit of agreement, –1.48 to 0.22). Repeatability and total imprecision (% CV) of the QS-RGQ assay were 1.0% and 1.1% at 2,000 IU/mL, and 0.7% and 1.4% at 20,000 IU/mL, respectively. Linearity of this assay ranged from 31.6 to 1.0±107 IU/mL, and the LOD was 2.95 IU/mL. Conclusions: The artus HBV QS-RGQ assay showed good performance but significantly decreased detection rate and viral load compared with CAP/CTM v2.0 assays. This assay recommends using plasma; however, we used stored serum because of the retrospective study design. Usually HBV DNA quantification is performed in plasma or serum, but sample type and clinical relevance of quantitative values should be considered when determining the clinical application of this reagent.

학교부적응 관심군과 정상군 고등학생의 진로인식에 대한 연구: 특성화고등학교 학생을 중심으로

한미순,박영신 한국아동학회 2022 한국아동학회 학술발표논문집 Vol.2022 No.4

청년학생문학론

한미순 중앙대학교 문리과대학 1991 해방광장 - 중앙대학교 문리과대학 Vol.4 No.-

설사환자에서 발생한 Campylobacter jejuni 균혈증 2예

한미순,김명숙,이양순,용동은,이경원 대한임상미생물학회 2014 Annals of clinical microbiology Vol.17 No.2

Campylobacter jejuni commonly causes bacterial en- teritis but rarely causes extraintestinal infection in- cluding bacteremia. We isolated C. jejuni from the blood culture of a 20-year-old man presenting with fever and headache and also from the blood culture of a 23-year-old man suffering abdominal pain and diarrhea. This organism grew in anaerobic culture, showed curved Gram-negative bacilli by Gram stain,and was identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). (Ann Clin Microbiol 2014;17:69-72)

Age-Specific Reference Values of Anti-Müllerian Hormone in Korean Women with Normal Menstruation: Time Trend and Clinical Suitability (2015–2021)

김희정,박진영,한미순 대한진단검사의학회 2022 Laboratory Medicine Online Vol.12 No.1

Anti-Müllerian hormone (AMH) levels can be affected by various factors, including age, lifestyle, and test method. This study aimed to review the time trend of AMH levels and the clinical suitability of current age-specific AMH reference values in Korean women. Population-based data of AMH levels, collected from 2015 to 2021 at a clinical laboratory, in Korean women aged 20–49 year with normal menstruation were evaluated (N=19,032 for Gen II assay [Beckman Coulter, USA]; N=14,497 for Access assay [Beckman Coulter, USA]). We found significant differences of AMH levels over time measured using the Gen II assay, but not those assessed by the Access assay. Based on current age-specific reference values, the AMH levels in Korean women with normal menstruation were considered relatively low in the groups at both age extremes (late 20s and late 40s). The AMH levels of Korean women did not show any time trends, except for the influence of the test method. We found that in the case of the Gen II assay, current age-specific AMH reference values, based on an AMH-age regression model, may not be clinically suitable for age groups at both extremes. Therefore, we established new age-specific AMH reference values measured using the Access assay for the general population.

Result Patterns and Characteristics of HBeAg and HBV DNA in Patients with Chronic Hepatitis B

최은진,김재한,한미순 대한진단검사의학회 2019 Laboratory Medicine Online Vol.9 No.4

BackgroundDiscrepancies in the results between hepatitis B e-antigen (HBeAg) and hepatitis B virus (HBV) DNA levels pose difficulties in the management of chronic hepatitis B (CHB). This study aims to better understand the different phases of CHB and to detect additional meaningful parameters for CHB patients. MethodsWe collected datasets of HBeAg and HBV DNA levels measured during 2016 and the follow-up results for CHB patients for past 3 years. We analyzed the collected data by applying the definitions of CHB clinical phase and compared the results of semi-quantitative and quantitative HBeAg assays. ResultsAbout 55% of 2,291 result pairs from CHB patients showed qualitative agreement between HBeAg and HBV DNA results. HBeAg (−) CHB was reported in 16.49%, while hepatitis B surface antigen (HBsAg) loss occurred in 0.18% among 1,146 patients annually. HBeAg reversion occurred in 2.74% of 839 patients that experienced HBeAg seroconversion. Patients with HBeAg (+) and HBV DNA (−) showed statistically significant differences in the levels and percentage abnormality of alanine aminotransferase (ALT) based on whether HBV DNA was ‘Target not detected’ or ‘Detected, <LOQ’. A strong correlation (r2=0.9435) was observed between semi-quantitative and quantitative HBeAg assay results. ConclusionsThis study reveals clinically important result patterns during the different phases of CHB. ALT level and percentage abnormality were significantly different based on HBV DNA status in HBeAg (+) and HBV DNA (−) patients. We suggest that clinical laboratories should report ‘HBV DNA (−)’ separately as ‘Target not detected’ and ‘Detected, <LOQ’.

최근 2년간 Polycheck Allergy 검사 결과의 분석: Skin Prick Test 및 ImmunoCAP과의 비교

정세리,장광천,조남준,한미순,김현숙,선제영,유종하 대한진단검사의학회 2012 Laboratory Medicine Online Vol.2 No.3

Background: Multiple Antigen Simultaneous Test (MAST)-immunoblot assay is a practical and economical test, which has been recently introduced nationwide. Authors investigated test efficiency of a MAST-immunoblot assay, Polycheck Allergy (PA). Methods: A total of 3,153 patients were tested by PA and the results were compared with the results of ImmunoCAP and skin prick test (SPT) in 532 and 75 patients, respectively. The correlation with the lgE results measured by VIDAS was also analyzed. Results: The agreements of PA with SPT were 87.8% in the Inhalant Panel and 89.3% in the Food Panel and the agreement of ImmunoCAP with SPT was 95.2%. The most common allergens giving positive reactions were Dermatophagoides farinae (46.2%) and Dermatophagoides pteronyssinus(40.0%). SPT taken as a reference, PA compared with ImmunoCAP showed higher agreement (D. farinae, 76.0 vs. 70.7%; D. pteronyssinus, 76.0 vs. 74.4%), sensitivity (D. farinae, 72.7 vs. 68.2%; D. pteronyssinus, 75.0 vs. 71.2%) and specificity (D. farinae, 85.0 vs. 81.3%) except for the specificity for D. pteronyssinus (78.3 vs. 87.5%). The rate of allergen specific IgE positive patients was higher than that of negative patients when total IgE was over 100 kU/L. Conclusions: Our results showed that the agreement, sensitivity and specificity of PA were similar to or better than those of the previously established test, ImmunoCAP. The allergen specific IgE results of PA were in correlation with total IgE. PA may be used for testing allergen specific IgE to diagnose and treat allergic diseases. 배경: Multiple Antigen Simultaneous Test (MAST)-immunoblot assay는 간편하고 경제적인 검사로 최근 국내에 도입되었다. 저자들은 MAST-immunoblot assay (Polycheck Allergy; Biocheck GmbH,Germany)의 검사 효용성을 알아보고자 하였다. 방법: Polycheck Allergy가 의뢰된 3,153명의 환자를 대상으로 분석을 실시하여 ImmunoCAP (Pharmacia AB, Sweden), 피부단자시험 결과와 각각 532명 및 75명의 환자에서 비교하였다. VIDAS (Biomerieux SA., France)로 측정한 총 IgE 결과와의 상관성도 분석하였다. 결과: 피부단자시험과의 일치율은 Polycheck Allergy 흡입형이87.8%, 음식형이 89.3%였고 ImmunoCAP은 95.2%이었다. 양성률은 D. farinae (46.2%), D. pteronyssinus (40.0%)가 가장 높은 비율을 차지하였으며 두 항원에 대해 피부단자시험을 기준으로 한일치율, 민감도, 특이도를 조사한 결과 Polycheck Allergy가 ImmunoCAP에비해 D. pteronyssinus의 특이도를 제외하고는 일치율(D. farinae; 76.0 vs. 70.7%, D. pteronyssinus; 76.0 vs. 74.4%), 민감도(D. farinae; 72.7 vs. 68.2%, D. pteronyssinus; 75.0 vs. 71.2%),특이도(D. farinae; 85.0 vs. 81.3%, D. pteronyssinus; 78.3 vs. 87.5%)모두가 높았다. 총 IgE는 100 kU/L 초과 시 특이 IgE 양성을 보이는환자가 음성을 보이는 환자보다 유의하게 많았다(흡입형 P<0.0001,음식형 P =0.0008). 결론: Polycheck Allergy는 기존 검사(ImmunoCAP)와 비슷하거나우수한 일치율, 민감도, 특이도를 보이고 VIDAS 총 IgE와도 연관성을 가지고 있어 알레르기 질환의 진단과 치료에 효과적으로 사용될 것으로 판단하였다.